Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | ($166.2M) | ($203.4M) | ($206.9M) | ($391.3M) | ($459.9M) | ($641.6M) | ($754.6M) | $29.6M | ($107.0M) | ($445.0M) | ($738.6M) | ($558.1M) | ($112.1M) | $263.5M | $2,096.9M | $1,176.8M | $2,711.7M | $2,342.1M | $3,322.0M | $3,619.6M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Vertex Pharmaceuticals Incorporated's last 12-month Net Income is ($479.8M), based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Vertex Pharmaceuticals Incorporated's Net Income growth was N/A. The average annual Net Income growth rates for Vertex Pharmaceuticals Incorporated have been N/A over the past three years, N/A over the past five years.